Polish biotech company on the road to international expansion: IMAGENE.ME with investment support from ABAN.VC and NCBR Investment Fund

IMAGENE.ME, a Polish biotechnology company that has been setting new standards in genomic testing, advanced genetic diagnostics and personalized health prevention for several years, is embarking on a dynamic expansion into foreign markets. The new PLN 6 million investment, made due to the strategic support of ABAN.VC and NCBR Investment Fund (NIF), will enable the company to enter international markets, strengthen its position in Poland and build the foundations for becoming a leader in Europe in the field of personal genomics in the area of health prevention and longevity.

IMAGENE.ME strategy: advanced solutions for health and longevity

IMAGENE.ME offers a unique, integrated personal genomics ecosystem. Key elements include advanced DNA analysis, expert-level interpretation of results, and preventive and diagnostic support available through the IMAGENE.ME LIFE app and platform. The platform provides access to continually updated results from the user’s genome, personalized health-promoting recommendations, teleconsultations with physicians, and recommendations of health products and services, making it a comprehensive tool for patients and medical partners.

“Our mission is to give everyone access to valuable information from a comprehensive genome study so they can consciously take care of their health. IMAGENE.ME gives patients the tools to translate DNA test results into real health-promoting actions,” says Dr. Miroslaw Kwasniewski, founder and vice chairman of the board of IMAGENE.ME. “Investment support from ABAN.VC and NIF allows us to take the next step in realizing this vision on a global scale.”

Expansion with partners focused on innovations

For ABAN.VC and NCBR Investment Fund, IMAGENE.ME is a partner that combines science, technology and a pragmatic business approach. With more than 10 active investments in its portfolio, the ABAN.VC fund saw in IMAGENE.ME a company with unique potential, ready to scale operations to international markets.

“IMAGENE.ME has shown that it cannot only provide innovative solutions, but also effectively address global needs in the area of health and longevity. The company has proven that it can enter a difficult medical market with an innovative solution, build partnerships and consistently strengthen its position in Poland. As it applies and develops a universal business model, we are supporting a company that has the potential to become a leader in Europe,” stressed Piotr Kupczak, CEO of ABAN VC.

NCBR Investment Fund operates with public funds with a mission to support Polish companies with high scientific and innovative potential, which can successfully make their mark on the international arena. In the case of IMAGENE.ME, the fund sees consistent efforts in transferring the latest scientific concepts and advanced technological solutions in genomics and large-scale biomedical data analysis to medical products and services.

IMAGENE.ME is a unique example of how a combination of technology, science and innovative approaches to market needs can create something truly unique in the Polish and European market for genomics and personalized medicine. We see in this project the potential to change the approach to personal genomics. The company brings significant value both medically, scientifically and commercially. The decision to support IMAGENE.ME stems from our belief that this is where the future of medicine lies: personalized, proactive and focused on long-term health support. IMAGENE.ME has tremendous opportunities ahead of it, and as an investor we will accompany it on the path of international expansion,” says Ksenia Wojcik-Karasiewicz, CEO of NCBR Investment Fund.

Integration of artificial intelligence and genomics – the future of personalized healthcare

IMAGENE.ME is also investing in the development of artificial intelligence technology. The company has an extensive, expertly developed knowledge base that forms the basis for building an advanced health assistant to support patients and medical professionals. AI integration will enable faster and more accurate health predictions and provide personalized recommendations in real time.

“Solutions that seemed like a vision a few years ago are being used more and more boldly today. In the area of genomics and genetic diagnostics, the scientific and medical world is beginning to recognize the role of inference from the study of the full genome and genetic variants for multigene traits analyzed together with clinical and behavioral (PRS) data. We are seeing studies where the integration of large language models (LLMs) in the patient-system-doctor relationship significantly improves understanding of outcomes and increases patient engagement in treatment and prevention efforts. These are directions we are developing and in which we have high hopes in the process of international expansion,” Dr. Kwasniewski stresses.

“When we created IMAGENE.ME several years ago, we knew we were several steps ahead of the market need, but we were consistent in our mission. Today, the market is changing – we are seeing a significant movement toward preventive health care, the use of integrated patient data, or building long-term, trust-based patient-doctor relationships. IMAGENE.ME meets these expectations. We are proud that the scientific vision has been transformed into solutions that have supported thousands of patients. We are pleased to see growing interest from partners in the medical market and strategic collaborations, such as our partnership with the DIAGNOSTYKA group in the implementation of the innovative LONGEVITY+ project. Artificial intelligence will bring us even closer to realizing our vision where everyone can use the results of genetic analysis in their daily lives, and medical professionals will have access to tools to help support patients more effectively. This is a future that is within reach,” adds Jacek Bajerski, Board Member for Operations and Technology.

IMAGENE.ME – towards new horizons in personalized medicine

Support from ABAN.VC and NCBR Investment Fund allows IMAGENE.ME to expand internationally and scale its business. The company is developing its own products and services in the area of personal genomics, while offering comprehensive support to partners in the health and prevention sectors, helping them adapt genomic solutions to their business needs. All this in order to achieve its mission and become a leader in personalized preventive health care based on genomic research.